EN | UA
EN | UA

Help Support

Back

Alpha-lipoic acid associated with reduced hepatic steatosis in NAFLD patients

Non-alcoholic fatty liver disease Non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease Non-alcoholic fatty liver disease

What's new?

For every 4 and 7 NAFLD patients, supplementation of Alpha-lipoic acid 1200 mg daily for 12 weeks, one achieves at least one and two grade improvements in hepatic steatosis, respectively.

A recent study has revealed favorable outcomes regarding the efficacy of alpha-lipoic acid (ALA) supplementation in combating hepatic steatosis among individuals with non-alcoholic fatty liver disease (NAFLD).

This randomized clinical trial led by Mehrangiz Ebrahimi-Mameghani et al. focused on evaluating the impact of ALA supplementation on inflammatory and metabolic markers (Fetuin-A, Sirtuin1 [SIRT-1], Cytokeratin 18 [CK-18]) associated with NAFLD in 50 patients.

These patients were divided into two groups to receive either two ALA capsules (ALA 600 mg per capsule plus vitamin E 400 mg daily) or two placebo capsules (together with vitamin E 400 mg daily). Results showed that ALA supplementation was significantly more effective than placebo in reducing hepatic steatosis by at least 1 grade. Noteworthy reductions in homeostasis model assessment for insulin resistance (HOMA-IR) score, insulin levels, and Fetuin-A levels in ALA supplemented group were found.

Source:

Journal of Functional Foods

Article:

Assessing the clinical and biochemical efficacy of alpha-lipoic acid in patients with non-alcoholic fatty liver disease: A randomized placebo-controlled clinical trial

Authors:

Mehrangiz Ebrahimi-Mameghani et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: